Oncology & Cancer
First successful treatment of pediatric high-risk refractory neuroblastoma with PARP inhibition
St. Jude Children's Research Hospital scientists report the first successful treatment of a pediatric patient with high-risk refractory neuroblastoma using a targeted therapy guided by clinical genomics.
Aug 15, 2024
0
8